top of page
AcelaBio, Inc

Histopathology and Precision Medicine Service provider

AcelaBio is a state-of-the-art contract research organization delivering end-to-end histopathology and precision medicine laboratory services for pharmaceutical, biotech and academic institutions. AcelaBio provides high throughput digital pathology services to support multicenter global clinical trials and has the flexibility to develop and validate biomarker assays for novel or existing protein or molecular targets. AcelaBio’s laboratory capabilities are applicable across a wide range of therapeutic indications including gastroenterology, oncology, and dermatology. AcelaBio is highly specialized in testing gastrointestinal tissues from patients with inflammatory bowel diseases (e.g., Crohn’s disease and ulcerative colitis), eosinophilic gastrointestinal diseases (e.g., eosinophilic esophagitis), and liver diseases (non-alcoholic steatohepatitis). AcelaBio employs operational, scientific, and medical experts, including U.S. Board Certified pathologists, who are dedicated to delivering reliable, high-quality data and imagery.


Sean Gui, MD

Service Provider:

USA CRO Biologics Clinical Preclinical Discovery On the Market

Demand Type:



December 31, 2025

Upcoming Conference

​Nov. 12th, 2022

CABS Conference

The BioPacific Conference is the annual flagship event of the CABS. Our mission is to bring scientists, executives, and bio-pharmaceutical professionals from the Pacific Rim countries together to discuss the latest advances in the world of life sciences, the unprecedented challenges and promises facing the industry, and the breath-taking developments and opportunities in Asia/Pacific countries


Back to Business

bottom of page